Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ: TARS · Real-Time Price · USD
90.78
+7.58 (9.10%)
At close: Sep 4, 2026, 4:00 PM EDT
91.25
+0.47 (0.52%)
After-hours: Sep 4, 2026, 4:44 PM EDT
Tarsus Pharmaceuticals Revenue
Tarsus Pharmaceuticals had revenue of $173.91M in the quarter ending June 30, 2026, with 69.41% growth. This brings the company's revenue in the last twelve months to $606.33M, up 105.17% year-over-year. In the year 2025, Tarsus Pharmaceuticals had annual revenue of $451.36M with 146.71% growth.
Revenue (ttm)
$606.33M
Revenue Growth
+105.17%
P/S Ratio
6.12
Revenue / Employee
$1,638,732
Employees
370
Market Cap
3.98B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 451.36M | 268.41M | 146.71% |
| Dec 31, 2024 | 182.95M | 165.51M | 948.62% |
| Dec 31, 2023 | 17.45M | -8.37M | -32.42% |
| Dec 31, 2022 | 25.82M | -31.21M | -54.73% |
| Dec 31, 2021 | 57.03M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Telix Pharmaceuticals | 890.79M |
| Iovance Biotherapeutics | 324.97M |
| IDEAYA Biosciences | 234.13M |
| Arcus Biosciences | 117.00M |
| AbCellera Biologics | 66.17M |
| Tango Therapeutics | 53.81M |
| uniQure | 18.67M |
| Relay Therapeutics | 10.35M |
TARS News
- 9 hours ago - Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care - GlobeNewsWire
- 1 day ago - Alkeus Announces Publication in JAMA Ophthalmology of Efficacy and Safety Results from the TEASE-1 Study of Gildeuretinol in Stargardt Disease - GlobeNewsWire
- 3 days ago - Tarsus to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 11 days ago - Alkeus Pharmaceuticals Announces Japan Ministry of Health, Labour and Welfare (MHLW) Has Granted Orphan Drug Designation to Gildeuretinol for Stargardt Disease - GlobeNewsWire
- 18 days ago - Tarsus Pharmaceuticals price target raised to $100 from $97 at Oppenheimer - TheFly
- 25 days ago - Tarsus Pharmaceuticals price target raised to $100 from $98 at Mizuho - TheFly
- 4 weeks ago - Tarsus to acquire Alkeus Pharmaceuticals for $450M upfront, up to $800M total - TheFly
- 4 weeks ago - Tarsus Pharmaceuticals reports Q2 EPS (43c), consensus (20c) - TheFly